UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Employees

8,600

Sector

Pharmaceuticals

Calendar

26/02 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
13/26/13	279.50 €	+2.12%	3,14,251
12/26/12	273.70 €	+3.67%	2,60,264
11/26/11	264.00 €	-0.38%	1,54,975
10/26/10	265.00 €	-0.49%	1,22,869
09/26/09	266.30 €	+1.64%	1,34,140

Real-time Euronext Bruxelles

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

UCB's promising outlook after H1 25 results, with clinical highlights

October 16, 2025 at 04:05 pm IST

UCB: Untouchable UCB; despite our upgrade

October 03, 2025 at 04:55 pm IST

More analyses

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

279.50EUR

Average target price

275.74EUR

Spread / Average Target

-1.35%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Bruxelles Other stock markets 10:25:00 13/02/2026 pm IST			5-day change	1st Jan Change
279.50 ^EUR	+2.12%		+6.68%	+17.14%

04/02	Lundbeck's Adjusted Earnings Exceed Expectations – Dividend Raised	FW
04/02	UCB says Bimzelx achieves inflammatory lesion resolution in Be Heard trials	RE

Capitalization	5.31TCr 6.3TCr 4.84TCr 4.62TCr 8.58TCr 5,70800Cr 8.92TCr 56TCr 22TCr 2,75700Cr 24TCr 23TCr 9,63400Cr	P/E ratio 2025 *	44.8x	P/E ratio 2026 *	32.6x
Enterprise value	5.36TCr 6.36TCr 4.88TCr 4.66TCr 8.66TCr 5,75700Cr 8.99TCr 57TCr 23TCr 2,78000Cr 24TCr 23TCr 9,71700Cr	EV / Sales 2025 *	7.03x	EV / Sales 2026 *	6.15x
Free-Float	61.3%	Yield 2025 *	0.51%	Yield 2026 *	0.52%

04/02	Lundbeck's Adjusted Earnings Exceed Expectations – Dividend Raised	FW
04/02	UCB says Bimzelx achieves inflammatory lesion resolution in Be Heard trials	RE
02/02	UCB on Track for 'Impressive' Growth Acceleration, Says RBC	MT
30/01	UCB says its Kygevvi recommended for approval in EU	RE
30/01	Indoco Remedies Limited Receives Final ANDA Approval from USFDA for Lacosamide Oral Solution USP, 10 mg/L	CI
21/01	Ocular Therapeutix, Inc. Appoints David W. Robinson As Global Chief Commercial Officer	CI
14/01	UCB SA Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 07:30 AM
07/01	BofA Reaffirms UCB's Buy Rating on Upbeat FY26 Outlook	MT
18/12	Bavarian Nordic as Appoints Anne Louise Eberhard as New Chair of the Board of Directors	CI
09/12	Lee's Pharmaceutical Holdings Limited acquires Staccato One Breath technology platform and assets, driving pipeline expansion and advancing global partnership with UCB through acquired rights	RE
08/12	UCB Estimates Lifted as BofA Expects Continued Pricing Tailwind in FY26	MT
08/12	UCB Presents Positive Results from GEMZ Phase 3 Study at AES Showing Fenfluramine Significantly Reduced Countable Motor Seizures in CDKL5 Deficiency Disorder	CI
08/12	UCB reports positive results from Gemz phase 3 study	RE

02/02	UCB on Track for 'Impressive' Growth Acceleration, Says RBC	MT
07/01	BofA Reaffirms UCB's Buy Rating on Upbeat FY26 Outlook	MT
03/12	Berenberg Keeps UCB at Buy Amid Plan to Maximize Growth of Key Assets	MT
29/25/29	UCB: UBS raises target price
14/25/14	Berenberg Says Higher Premium for UCB Pipeline Warranted; Price Target Raised	MT

UCB Share Price

Equities

UCB

BE0003739530

Pharmaceuticals

Valuation: UCB

Chart: UCB

Latest news: UCB

Last Transcript: UCB

Analysts' recommendations: UCB

Press Releases: UCB

News in other languages: UCB

Trading UCB

Quotes and Performance

Course Extremes

Managers and Directors: UCB

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

04/02	UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements	PU
30/01	UCB : KYGEVVI (doxecitine and doxribtimine) recommended for approval in the European Union as treatment for Thymidine Kinase 2 Deficiency (TK2d)	PU
19/01	UCB : Financial Reporting Document	PU
14/01	Innovation and Execution Power UCB's Success	AQ
13/01	UCB : Innovation and Execution Power UCB’s Success	PU

13/02	Avis d'analystes du jour : Legrand et AB Inbev séduisent, Adyen pas du tout
13/02	Le "trade de la peur" sur l'IA fait son retour
04/02	UCB presenteert nieuwe studiedata rond EHSF
03/02	KBC Securities positiever over UCB
02/02	UCB blijft een mooie koopkans

1 day	+2.12%
1 week	+6.68%
Current month	+9.44%
1 month	+7.67%
3 months	+23.18%
6 months	+43.85%
Current year	+17.14%

1 week	260.6	279.5
1 month	250.1	279.5
Current year	232.5	279.5
1 year	129.35	279.5
3 years	65.4	279.5
5 years	65.4	279.5
10 years	54.84	279.5

Manager	Title	Age	Since
Jean-Christophe Tellier CEO	Chief Executive Officer	67	01/01/2015
Sandrine Dufour DFI	Director of Finance/CFO	59	01/07/2020
Antje Witte IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Charles-Antoine Janssen BRD	Director/Board Member	55	01/01/2012
Jean-Christophe Tellier BRD	Director/Board Member	67	01/01/2015
Jonkheer Cédric van Rijckevorsel BRD	Director/Board Member	56	24/04/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
UCB	+2.12%	+6.68%	+54.89%	+259.90%	6.3TCr
REGENERON PHARMACEUTICALS, INC.	+2.49%	+2.25%	+19.24%	+6.75%	8.24TCr
SAMSUNG BIOLOGICS CO.,LTD.	-0.52%	+71.00%	+71.00%	+71.00%	5.49TCr
CSL LIMITED	+1.40%	-15.70%	-41.13%	-49.82%	5.11TCr
BIOGEN INC.	+0.52%	-2.32%	+43.10%	-29.56%	2.88TCr
INCYTE CORPORATION	+0.35%	-6.73%	+43.57%	+27.41%	2.01TCr
INNOVENT BIOLOGICS, INC.	-0.17%	+3.51%	+129.61%	+113.27%	1.97TCr
MODERNA, INC.	+5.29%	+2.97%	+28.01%	-76.18%	1.65TCr
SWEDISH ORPHAN BIOVITRUM AB	-0.73%	+2.98%	+31.74%	+67.74%	1.58TCr
BRIDGEBIO PHARMA, INC.	-1.06%	+10.58%	+115.62%	+516.80%	1.45TCr
Average	+0.96%	+1.19%	+49.56%	+90.73%	3.67TCr
Weighted average by Cap.	+1.25%	+0.18%	+38.56%	+75.02%

	2025 *	2026 *
Net sales	761.44Cr 903.67Cr 694.5Cr 663.04Cr 1.23TCr 82TCr 1.28TCr 8.08TCr 3.21TCr 40TCr 3.39TCr 3.32TCr 1,38100Cr	847.17Cr 1.01TCr 772.69Cr 737.7Cr 1.37TCr 91TCr 1.42TCr 8.99TCr 3.57TCr 44TCr 3.77TCr 3.69TCr 1,53700Cr
Net income	119.97Cr 142.39Cr 109.43Cr 104.47Cr 193.93Cr 13TCr 201.49Cr 1.27TCr 505.27Cr 6.23TCr 533.98Cr 523Cr 22TCr	160.46Cr 190.43Cr 146.35Cr 139.72Cr 259.37Cr 17TCr 269.48Cr 1.7TCr 675.77Cr 8.33TCr 714.16Cr 699.47Cr 29TCr
Net Debt	45Cr 54Cr 41Cr 40Cr 73Cr 4.88TCr 76Cr 481.76Cr 191.25Cr 2.36TCr 202.12Cr 197.96Cr 8.24TCr	-101.61Cr -120.6Cr -93Cr -88Cr -164.25Cr -11TCr -170.65Cr -1.08TCr -427.95Cr -5.27TCr -452.26Cr -442.96Cr -18TCr